Avtor/Urednik		Schara, R; Medvešček, M; Skalerič, U
Naslov		Zdravljenje parodontitisa z Arestinom pri bolnikih s sladkorno boleznijo
Prevedeni naslov		Periodontal treatment with Arestin in diabetic patients
Tip		članek
Vir		Zobozdrav Vestn
Vol. in št.		Letnik 59, št. 4-5
Leto izdaje		2004
Obseg		str. 139-45
Jezik		slo
Abstrakt		Background: The aim of Ihis randomised pilot clinical trial was to determine if type 1 diabetic patients with periodontitis will experience a reduction in HbA1c levels when treated with locally delivered minocycline microspheres (Arestin) as an adjunct to scaling and root planing. Subjects and methods: Twenty adult patients with poorly controlled diabetes (HbA1c > 7.5%) and periodontitis. as determined by the presence of four teeth with > 5 mm periodontal pockets, were included in the study. Two of the patients had 6-9 mm pockets and bleeding on probing. All patients received full-mouth scaling and root planing at baseline. In the test group (10 patients), Arestin was applied into all pockets > 5 mm at baseline and again at 12 weeks. Probing depth (PD), clinical attachment level (CAL), plaque lndex (PI), gingival index (GI). and HbA1c were evaluated at baseline and at 6, 12, 18 and 24 weeks. Results: The results showed that local administration of Arestin as an adjunct to scaling and root planing was significantly more effective in reducing probing depths and providing a gain in clinical attachment levels than scaling and root planing alone. Hb1Ac levels were reduced in all patients, but the difference between the test and control groups was not significant. Conclusions: We conclude that local administration of Arestin in conjunction with scaling and root planing significantly reduces the probing depth in type I diabetic patients.
Izvleček		Izhodišče: Namen raziskave je bil ugotoviti vpliv in učinkovitost zdravila minociklin v mikrosferah (Arestin). dodanega po začetni fazi parodontalnega zdravljenja, na zmanjšanje ravni glikiranega hemoglobina (HbA1c) pri bolnikih s sladkorno boleznijo tipa 1 in kroničnim parodontitisom. Preiskovanci in metode: V raziskavi je sodelovalo dvajset bolnikov (10 žensk in 10 moških). Imeli so slabo metabolno urejenost in raven glikiranega hemoglobina večjo od 7.5%, najmanj 10 zob v funkclonalni denticiji (brez tretjih kočnikov), prisotne štiri zobe v najmanj dveh kvadraniih s parodontalnimi žepi, globljimi od 5 mm, od katerih sta dva imela 6-9 mm globoke parodontalne žepe in sta krvavela ob sondiranju. Pri bolnikih testne in kontrolne skupine je bila na začetku raziskave opravljena začetna faza parodontalnega zdravljenja. Testni skupini smo dovajali Arestin v vse parodontalne žepe. globlje od 5 mm, na začetku ter 12. teden raziskave. Izsledki: Po zdravljenju so se izboljšali parodontalni klinični parametri, metabolična urejenost bolnikov, globina sondiranja in izguba kliničnega prirastišča sta bili v testni skupini statistično značilno nižji kot pri kontrolni skupini. Zaključek: Rezultati raziskave so pokazali. da je zdravljenje parodontitisa pri sladkornih bolnikih bolj uspešno, če poleg začetne faze parodontalnega zdravljenja uporabimo tudi lokalno zdravljenje z Arestinom.
Deskriptorji		DIABETES MELLITUS, INSULIN-DEPENDENT PERIODONTITIS MINOCYCLINE DENTAL PLAQUE INDEX PERIODONTAL INDEX HEMOGLOBIN A, GLYCOSYLATED ADMINISTRATION, TOPICAL TREATMENT OUTCOME